This study was designed as a placebo-controlled, forced dose-titration trial, and, therefore, no active comparator was employed and subjects may not have been receiving a dose of LDX that provided optimal balance between efficacy and tolerability.
The study is designed as a five arm randomised controlled trial with three active interventions and two comparators.
This study was designed as a population-based retrospective cohort study using data from a national administrative database with 1 4 gender- and age-matched comparators followed up to 8 years or until a diagnosis of malignancy was given.
DEVOTE is a phase 3b, multicenter, international, randomized, double-blind, active comparator-controlled trial, designed as an event-driven trial that would continue until 633 positively adjudicated primary events were accrued.
Differential current conveyor II (DCCII) is designed, modified, and exploited as a comparator with reduced propagation delay and power consumption.
Patients were randomized to either ETN + MTX (N = 197) or DMARD + MTX (N = 103) in an open-label, active-comparator, multicenter study, with PRO measures designed as prospective secondary endpoints.
For this reason TENS was chosen as a comparator treatment for a new device designed to help those patients with chronic back pain who continue to have serious difficulties, despite not being a treatment endorsed by current guidelines [ 1].
Although RCTs using placebo as a comparator fulfil the design criteria for marketing authorization (EMA and FDA), the use of a drug in clinical practice would require evidence in line with the Comparative Effectiveness Research CERR) paradigm [ 111].
The POS was added as a comparator since it is shorter (12 items) and was designed for clinical use (as opposed to the EORTC tools, which were primarily designed for use in research settings).
The second study, of Chinese subjects primarily with early stage CKD, was designed to look for differences between CKD subgroups and did not include healthy patients as a comparator [ 22].
